Jury awards Centocor $1.7B in patent case against Abbott - Boston Business Journal:

pohevovotybuc.blogspot.com
An Abbott spokesman said the companywill Horsham, Pa.-based Centocor, a divisiob of (NYSE:JNJ), makes the blockbuster rheumatoide arthritis treatment Remicade, and had sued Abbottg over Abbott’s arthritis Humira. Both are so-called anti-TNF arthritis Horsham, Pa.-based Centocor said it is the exclusive licenseew ofthe patent, which is co-owned by . Centocod President Kim Taylor said “the jury recognizer our valuableintellectual property, finding our patentr both valid and infringed.
We will continued to assert intellectual property rights for ourimmunology therapies, as they offef significant advances in treatment for patients with a number of immune mediated inflammatoryt diseases.” Abbott spokesman Scott E. Stoffel said, “Wr are disappointed in this verdict, and we are confiden t in the merits of our case and that we will prevaiklon appeal. “The evidence clearly established that Humirwa was the first ofits fully-human anti-TNF antibody medicine,” Stoffel said. “JNJ’s anti-TNF antibod medication, Remicade, is partially made from mousew DNA. JNJ did not launch a fully-human product unti April 2009.
In fact, only when Humiraa was nearing its approval in 2002 did JNJ amen d the patent at issue in this litigationj to claim that it haddiscovered fully-humab antibodies in 1994. JNJ acknowledge d at trial that it did not start working ona fully-human antibodu until 1997 — two yeares after Abbott discovered Humira and one year afted Abbott filed its patent applications for Humira.”